Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Link Between Gene Fusion and Bladder and Brain Cancer

By University of Warwick | August 31, 2017

A study by the University of Warwick sheds new light on gene fusion in bladder and brain cancer. Researchers have found that a previously overlooked part of a specific gene fusion has a worsening effect on cancer cells. They have also found that preventing cell ‘signalling’ from this particular fusion may not be an effective route for future cancer treatment research.

Their findings have just been published in the paper FGFR3–TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle in the Royal Society journal Open Biology. Sometimes chromosomes can break and get reattached to a different one in an unusual way which results in a fusion between one gene and another which makes a new gene, called a gene fusion.

The scientists at Warwick Medical School examined the gene fusion FGFR3-TACC3 which is associated with bladder and brain cancers. Previously scientists focused on the first part of the fusion, FGFR3, because this was known to be associated with cancer. However the team decided to look at the second half TACC3 or transforming acidic coiled-coil protein 3. They found that this part of the fusion causes mistakes in cell division, making the cancer worse.

The team was led by Professor Stephen Royle who said: “Cancer cells often have gene fusions which happen because the DNA in cancer cells is really messed up such as the well-known Philadelphia chromosome in chronic myelogenous leukaemia.

“A few years ago, a new fusion was discovered in bladder and brain cancers, called FGFR3-TACC3. Previously most of the emphasis has been on the former part of the fusion. However we found that the latter part of the fusion causes mistakes in cell division which could make the cancer worse.

“Doing work like this is important as it helps us to understand all the possible ways to tackle a specific cancer and to find any problems with potential treatments”

Many gene fusions have been found to be the result of a protein that continues to send a signal to the cell when it shouldn’t. It is thought that this transforms the cell to divide uncontrollably as is the case in FGFR3-TACC3; FGFR3 can send signals and TACC3 is thought to make it do this uncontrollably. TACC3 is important for cell division as it helps chromosomes to separate to the two ‘daughter’ cells when a cell divides. Chromosomes are shared out by the mitotic spindle which is built inside the cell made up of tiny threads called microtubules. TACC3 stabilises these microtubules and adds strength to the mitotic spindle.

Previously scientists suggested that the gene fusion FGFR3-TACC3 might bind to the mitotic spindle but not be able to work properly. Professor Royle’s team decided to examine this in further depth. However the team found that FGFR3-TACC3 is not actually bound to the mitotic spindle. Instead it is at the cell’s membrane and in small vesicles in the cell. They found that the TACC3 section of the fusion gene FGFR3-TACC3 was acting like a vacuum cleaner ‘hoovering’ the normal TACC3 off the spindle, preventing normal cell division.

The team used a process of elimination to further their research. First they made the cancer cells express some normal TACC3 and this repaired the faulty division. They then removed the FGFR3-TACC3 fusion and that also returned the cells back to normal. Finally they made a fake FGFR3-TACC3 with a dummy part in place of FGFR3 and they found that this also caused problems by hoovering up normal TACC3 and causing cell division.

Professor Royle said: “An ideal cancer treatment might be to block TACC3 interactions as well as stopping signalling. However this is very difficult to do and is far in the future.

“Drug companies can develop chemicals which stop cell signalling from fusions and these could work as anti-cancer agents.

“In the case of FGFR3-TACC3 even if you stop the signalling there will still be cell division problems in the cancer cells. We hope our study will provide a basis for further research into how these gene fusions are linked to bladder and brain cancer.”


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE